

DAFTAR PUSTAKA

1. Al-Khawalden OA, Al-Hassan MA, Froeliches ES. *Self-efficacy, self-management, and glycemic control in adults with type 2 diabetes mellitus*. Elsevier. 2012 : 10-16.
2. Shrivastava SA, Shrivastava PS, Ramasamy J. *Role of self-care in management of diabetes mellitus*. J Diab Met. 2013 : 1-5.
3. American Diabetes Association. 2013. *Diagnosis and classification of diabetes mellitus*. Diab Care : S67-74.
4. Cade WT. *Diabetes-related microvascular and macrovascular disease in physical therapy setting*. J Phys Ther. 2008 November; 88(11) : 1322-35.
5. M Rob, Dam V. *The epidemiology of lifestyle and risk for type 2 diabetes mellitus*. J Epid. 2003 Des : 1115-25.
6. Catherwood MA, Rowell LA, Anderso P, et al. *Glucose-induced oxidative stress in mesangial cells*. Kidney Intr. 2002;61:599-608.
7. Singh P, Crook D. *Hexosamine Regulation of Glucose-Mediated Laminin Synthesis in Mesangial Cell Involves Protein Kinase A and C*. J Phy Renal Phy. 2000: F646-54.
8. Erensoy N, Yilmazer S, Ozturk M, et al. *Effect of ACE inhibition on the expression of type IV collagen and laminin in renal glomeruli in experimental diabetes*. Elsevier. 2004 April: 280-7.
9. Publiese G, Pricci T, Publiese F, et al. *Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells*. Diabetes. 1994;43: 478-90.
10. U Qian L, Yin X-X, Wang Jian-Yun, et al. *Effects of Ginkgo biloba on prevention of development of experimental diabetic nephropathy in rats*. Octa Pharm. 2007 Jun;28(6): 818-26
11. Zhang L, Pang S, Deng B, et al. *High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-Kb/NADPH*

- oxidase/ROS pathway which is inhibited by resueratrol*. Elsevier. 2012 January 9 : 629-38.
12. Mcgrowder DA, Jackson LA, Crawford TV. *Biochemical Evaluation of Oxidative Stress in Type 1 Diabetes*. Intech. 2013: 223-48
 13. Whiteside CI. *Cellular mechanisms and treatment of diabetes vascular complications converse on reactive oxygen species*. ISSN. 2005;7: 148-54.
 14. Jay M. Patel : *A review potential health benefits of flavonoids*. LURJ. 2008;(3): 1-5.
 15. Har LW, Ismail IS. *Antioxidant activity, total phenolic and total flavonoid of syzygium polianthum (Wight) Walp leaves*. Med Arom Plants. 2012: 219-28.
 16. Mun'im A, Hanani E. *Fisioterapi Dasar*. Jakarta: Dian Rakyat.
 17. Perumal S, Mahmud R, Piaru SP, et al. *Potenstial antiradical activity and cytotoxicity assessment of ziziphus mauritiana and syzygium polyanthum*. Int J of Pharm. 2012;8(6): 534-41.
 18. Suharmiati, Roosihermiatie B. *Studi pemafaatan dan keamanan kombinasi metformin dengan ekstrak campuran andrographis paniculata dan syzgium polyanthum untuk pengobatan diabetes melitus*. BPPKK. 2012 Januari: 110-19.
 19. Khan A, Zaman G, Anderson RA. *Bay Leaves Improve Glucose and Lipid Profile of People with Type 2 Diabetes*. J. Clin. Biochem Nutr. 2009 January;44: 52-6.
 20. Fithriana D. *Pengaruh pemberian Morinda citrifolia L. Terhadap fungsi ginjal diabetes nefropati pada tikus sprague dawley yang diinduksi streptozotocin (STZ) kajian kadar albumin urin, NO, ekspresi laminin mesangial*. Tesis magister ilmu biomedik FK Undip. 2011. 1-76.
 21. Srinivasan K, Ramarao P. *Animal models in type 2 diabetes research : An overview*. J Med Res. 2007 March : 451-472.
 22. Hyun S. *Role of TGF- β in Mesangial Matrix Accumulation in Chronic Progressive Glomerular Disease, An Update on Glomerulopathies-Etiology and Pathogenesis*. Prabhakar S, editor. Europe : ISBN, 2011. 124P.

23. Ha TS, Barnes JL, Stewart JL, et al. *Regulation of renal laminin in mice with type II diabetes*. J Am Soc Nephrol. 1999;19:35-9.
24. Menan MC, Chuang PY, He CJ. *The Glomerular Filtration Barrier : Components and Crosstalk*. Int J Nephro. 2012 June 5: 1-9.
25. Setty S, Michael AA, Mauer M, et al. *Differential expression of laminin isoforms in diabetic nephropathy and other renal disease*. Mod Pathol. 2012 June; 25(6) : 859-68.
26. Biolamina. *Human recombinant lamina-421*. 2014. Available at <http://www.biolamina.com/products/lamina-421>.
27. Jefferson JA, Shankland SJ, Pichter RH. *Proteinuria in diabetic kidney disease: A mechanistic viewpoint*. Kidney Int. 2008 April : 22-36
28. Geoffroy K, Wiernsperger N, Lagarde M, et al. *Lipids and lipoproteins : Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipid*. J Biochem. 2004 June 7: 34343-52
29. Krishan P, Chakkarwar VA. *Diabetic nephropathy : aggressive involvement of oxidative stress*. J Pharm Educ Res . 2011 June : 35-41
30. Saleh MA. *Role of endothelial-1(ET-1) in glomerular inflammation and glomerular permeability in normal and diabetic kidneys*. Proquest. 2010 : 1-213.
31. Goldin A, Beckman JA, Schmidt M, et al. *Advanced glycation end product: sparking the development of diabetic vascular injury*. Circulation. 2006;114 : 597-605.
32. Bonke VT, Lindschau C, Rizkalla B, et al. *Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C- α dependent pathway*. Diabetes. 2004 : 2921-2930.
33. Brownlee M. *Banting Lecture 2004 The Pathobiology of Diabetic Complications. A Unifying Mechanism*. Diabetes 2005;54: 1615-35.
34. Noh H, King GL. *The Role of Protein Kinase C Activation in Diabetic Nephropathy*. Kidney Int. 2007: S49-53.

35. Davis LK, Rodgen BD, Kelly KM. *Angitensin II and glucose stimulated extrasellular matrix production:mediation by the insulin-like growth factor (IGF) axis in murine mesangial cell line*. Endocrine. 2008 February;33(1): 32-39.
36. Alsaad KO, Herzengberg AM. *Distinguishing Diabetes Nephropathy from Other Causes of Glomerulosclerosis: an Uptade*. J Clin Pathol. 2007;60: 1-9.
37. Depkes RI. *Materia Medika Indonesia*. Jakarta : Depkes RI, 1980.
38. Yohana ANA. *Khasiat Tanaman Obat*. Jakarta : Pustaka Buku Murah, 2008.
39. Agus SAW. *The Use of Bay Leaf (Eugenia Polyantha Wight) in Dentistry*. Dental J. 2008: 3.
40. Kusuma IW, Kuspradi H, Arung ET, et al. *Biological activity and phytochemical analysis of three Indonesian medical plants, murraya koenigii, syzygium polyanthum and zingiber purpurae*. Elsevier. 2011 Jan;4(1) : 75–79.
41. Studiawan H, Santosa MH. *Uji aktivitas penurunan kadar glukosa darah ekstrak daun eugenia polyantha pada mencit yang diinduksi aloksan*. Media kedokteran hewan. 2005. 62-5.
42. Lelono RAA, Tachibana S, Itoh K. *In vitro antioxidative activities and polyphenol content of eugenia polyantha wight grown in Indonesia*. J Bioscienc. 2009 : 1564-70.
43. Giugliano D, Ceriello A, Esposito AK. *Glucosa metabolism and hyperglycemia*. American Journal Clinical Nutrition. 2008: 217S-22S
44. Akbarzadeh A, Norouzi D, Mehrabi MR, et al. *Induction of Diabetes By Streptozotocin in Rats*. J Clinic Biochem. 2007; 22(2): 60-4.
45. Arora S, Ojha SK, Vohora D. *Characterisation of Streptozotocin Induced Diabetes Melitus in Swiss Albino Mice*. Global Journal of Pharmacology. 2009; 3(2): 81-4
46. Szkudelski T. *The Mechanism of Alloxan and Streptozotocin Action in B Cell of theRat Pancreas*. Physiological Research. 2001; 50: 536-46.

47. Tesch GH, Terri J, Allen T. *Methods in Renal Research, Rodent Models of Streptozotocin-Induced Diabetic Nephropathy*. *Nephrology*. 2007;12: 261-66.
48. Sastroasmoro S dan Ismail. *Dasar-dasar metodologi penelitian klinis*. Edisi 3. Jakarta : Sagung Seto, 2008 : 93-111.
49. World Health Organization. *Research guidelines for evaluating the safety and efficacy of herbal medicine*. 1993: 44.
50. Tuneda S, Pippin JW, Sage EH, et al. *Amelioration of diabetic nephropathy in SPARC-null mice*. *J Am Soc Nephrol*. 2003;14: 968-80.
51. Lukacino A, Mojzis J, Benacka, et al. Preventive effects of flavonoids on alloxan induce DM in rats. *Acta Vet-Bino*. 2008, 77: 175-182.
52. Desai NK, Bhabhor PH, et al. Role of antioxidant therapy in management of type-2 diabetes mellitus. *NJIRM*. 2013; vol. 4(2). March-April: 128-133.

